In vivo inhibition of CXCL12 in CML using a targeted RNA oligonucleotide (NOX-A12/olaptesed pegol) was synergistic with TKI, suggesting that enhanced CML mobilisation out of the BME sensitised these cells to BCR::ABL1 inhibition [30]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.